Deep Remission Tied to RA Control - Takeaways - MDSpire
From the Journals

Deep Remission Tied to RA Control

At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.

  • By

  • Andrea Surnit

  • May 6, 2026

  • 4 min

Share

  • 1

    Clinical deep remission (CliDR) offers better long-term outcomes in rheumatoid arthritis.

  • 2

    63% of the CliDR group maintained sustained remission at 5 years.

  • 3

    DAS28-CRP is used to assess disease activity.

  • 4

    Tapering medications increases relapse risk, especially in non-CliDR patients.

  • 5

    Study highlights the prognostic importance of remission depth when considering treatment reduction.

  • 6

    Observational study limits generalizability due to selection bias.

  • 7

    CliDR effectively indicates absence of joint inflammation.

Original Source(s)

Deep Remission Tied to RA Control

  • by Andrea Surnit

  • May 6, 2026

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Tofacitinib vs Adalimumab Findings Require Caution in RA

Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.